EVOKE PHARMA, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 11 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-10-18: Reporting owner Smeal Benjamin C.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-08-07: Reporting owner Kowieski Mark; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-08-07: Reporting owner CARLSON MARILYN R.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-08-07: Reporting owner D'Onofrio Matthew J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-10-18 | Smeal Benjamin C. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,833 5,833 owned after | $5.51 exercise price | 2024-10-22 | |
| 2024-08-07 | Kowieski Mark Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,291 17,291 owned after | $5.27 exercise price | 2024-08-08 | |
| 2024-08-07 | CARLSON MARILYN R. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,291 17,291 owned after | $5.27 exercise price | 2024-08-08 | |
| 2024-08-07 | D'Onofrio Matthew J Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +64,840 64,840 owned after | $5.27 exercise price | 2024-08-08 | |
| 2024-05-30 holding as of filing | Kowieski Mark Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.09 exercise price | 2024-05-30 | ||
| 2024-05-30 holding as of filing | Kowieski Mark Officer (Chief Financial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.01 exercise price | 2024-05-30 | ||
| 2024-05-22 | Hill Malcolm R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,625 14,625 owned after | $0.45 exercise price | 2024-05-24 | |
| 2024-05-22 | GARNER CAM L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,750 17,750 owned after | $0.45 exercise price | 2024-05-24 | |
| 2024-05-22 | REED VICKIE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +15,000 15,000 owned after | $0.45 exercise price | 2024-05-24 | |
| 2024-05-22 | WIDDER KENNETH J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,250 14,250 owned after | $0.45 exercise price | 2024-05-24 | |
| 2024-05-22 | Brady Todd C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +14,625 14,625 owned after | $0.45 exercise price | 2024-05-24 |